Skip to main content
Journal cover image

Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites.

Publication ,  Journal Article
Dong, OM; Roberts, MC; Wu, RR; Voils, CI; Sperber, N; Gavin, KL; Bates, J; Chanfreau-Coffinier, C; Naglich, M; Kelley, MJ; Vassy, JL; Rivas, S ...
Published in: Pharmacogenomics
November 2021

Aim: The first Plan-Do-Study-Act cycle for the Veterans Affairs Pharmacogenomic Testing for Veterans pharmacogenomic clinical testing program is described. Materials & methods: Surveys evaluating implementation resources and processes were distributed to implementation teams, providers, laboratory and health informatics staff. Survey responses were mapped to the Consolidated Framework for Implementation Research constructs to identify implementation barriers. The Expert Recommendation for Implementing Change strategies were used to address implementation barriers. Results: Survey response rate was 23-73% across personnel groups at six Veterans Affairs sites. Nine Consolidated Framework for Implementation Research constructs were most salient implementation barriers. Program revisions addressed these barriers using the Expert Recommendation for Implementing Change strategies related to three domains. Conclusion: Beyond providing free pharmacogenomic testing, additional implementation barriers need to be addressed for improved program uptake.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Pharmacogenomics

DOI

EISSN

1744-8042

Publication Date

November 2021

Volume

22

Issue

17

Start / End Page

1121 / 1133

Location

England

Related Subject Headings

  • Young Adult
  • Veterans
  • United States Department of Veterans Affairs
  • United States
  • Pharmacology & Pharmacy
  • Pharmacogenomic Testing
  • Middle Aged
  • Male
  • Humans
  • Health Resources
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Dong, O. M., Roberts, M. C., Wu, R. R., Voils, C. I., Sperber, N., Gavin, K. L., … Voora, D. (2021). Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites. Pharmacogenomics, 22(17), 1121–1133. https://doi.org/10.2217/pgs-2021-0089
Dong, Olivia M., Megan C. Roberts, R Ryanne Wu, Corrine I. Voils, Nina Sperber, Kara L. Gavin, Jill Bates, et al. “Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites.Pharmacogenomics 22, no. 17 (November 2021): 1121–33. https://doi.org/10.2217/pgs-2021-0089.
Dong OM, Roberts MC, Wu RR, Voils CI, Sperber N, Gavin KL, et al. Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites. Pharmacogenomics. 2021 Nov;22(17):1121–33.
Dong, Olivia M., et al. “Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites.Pharmacogenomics, vol. 22, no. 17, Nov. 2021, pp. 1121–33. Pubmed, doi:10.2217/pgs-2021-0089.
Dong OM, Roberts MC, Wu RR, Voils CI, Sperber N, Gavin KL, Bates J, Chanfreau-Coffinier C, Naglich M, Kelley MJ, Vassy JL, Sriram P, Heise CW, Rivas S, Ribeiro M, Chapman JG, Voora D. Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites. Pharmacogenomics. 2021 Nov;22(17):1121–1133.
Journal cover image

Published In

Pharmacogenomics

DOI

EISSN

1744-8042

Publication Date

November 2021

Volume

22

Issue

17

Start / End Page

1121 / 1133

Location

England

Related Subject Headings

  • Young Adult
  • Veterans
  • United States Department of Veterans Affairs
  • United States
  • Pharmacology & Pharmacy
  • Pharmacogenomic Testing
  • Middle Aged
  • Male
  • Humans
  • Health Resources